Quantum BioPharma Licensee Unbuzzd Appoints Michael 'Zappy' Zapolin as CEO to Lead Public Listing and National Rollout
Found this article helpful?
Share it with your network and spread the knowledge!
Quantum BioPharma Ltd. (NASDAQ: QNTM) announced that its licensee, Unbuzzd Wellness Inc., has appointed Michael Zapolin as CEO. Zapolin, known as “Zappy,” will lead efforts to finance and list Unbuzzd on a stock exchange, followed by a nationwide commercial marketing and product rollout in the United States. The transition to a publicly listed company is scheduled to go effective in the next quarter, with former CEO Richard Buzbuzian assisting in the process. Unbuzzd markets unbuzzd™, a beverage designed to accelerate alcohol metabolism, restore mental clarity, and reduce hangover symptoms.
This news matters because it signals a significant step forward for a product that has already garnered attention in the wellness and beverage sectors. The appointment of a CEO with a mandate to take the company public and execute a national rollout could rapidly scale Unbuzzd’s market presence. For Quantum BioPharma, which retains a 19.84% ownership stake (as of March 31, 2026) and royalty payments of 7% of sales until payments reach $250 million, after which the royalty drops to 3% in perpetuity, the success of Unbuzzd could translate into substantial financial returns. Moreover, Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses, preserving its core biopharma focus.
The implications extend beyond Quantum. The functional beverage market has seen growing consumer interest in products that mitigate the effects of alcohol. Unbuzzd’s peer-reviewed clinical study backing its claims may give it a competitive edge. With Zapolin at the helm, the company aims to capitalize on this momentum. The planned public listing could provide Unbuzzd with the capital needed to expand distribution and marketing, potentially making it a notable player in the wellness industry. For investors, this development offers a window into Quantum’s strategy of spinning out consumer-facing assets while retaining royalty streams and pharmaceutical rights.
Quantum BioPharma itself remains focused on developing treatments for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is advancing Lucid-MS, a patented new chemical entity shown in preclinical models to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The dual approach of advancing drug candidates while monetizing consumer products like unbuzzd™ demonstrates a diversified business model that could appeal to a broad investor base.
InvestorWire, a specialized communications platform, disseminated this announcement. InvestorWire is part of the Dynamic Brand Portfolio at IBN, which provides access to wire solutions, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions. For more information, visit InvestorWire. The full press release can be viewed at https://ibn.fm/CBNq1. Investors can also find updates on Quantum BioPharma at Quantum BioPharma Ltd.